KRAS and intrahepatic cholangiocarcinoma: Zou et al. [40] evaluated 103 patients with cholangiocarcinoma in China and found that TP53-defective ICC patients are more likely to be HBsAg-seropositive, whereas mutations in the oncogene KRAS are nearly exclusively found in HBsAg-seronegative ICC patients.